Sponsors and CROs Rely on Analytics in Clinical Research but Are Limited to Traditional and In-House Data, Medidata Finds
June 21 2017 - 8:30AM
Business Wire
Survey Results Reveal Top Challenges Facing
Life Sciences Companies Today, as Well as Emerging Data Sets,
Technologies and Trends to Alleviate Hurdles in Drug
Development
Medidata (NASDAQ:MDSO), the leading global provider of
cloud-based technology and data analytics for clinical research,
today announced results of an industry survey to better understand
how global life sciences companies think about and use data in
clinical research. Conducted in partnership with PharmaVOICE
magazine and titled “Using Data and Analytics in Clinical
Development,” the survey revealed that 90% of respondents rely on
some form of analytics solution—viewing data as a critical element
for achieving their R&D priorities—but are limited to their own
data to make strategic decisions.
Garnering insights from nearly 200 life sciences executives
across pharmaceutical companies, contract research organizations
(CROs), biotech companies and medical device developers, the survey
indicated that reducing clinical research timelines was the number
one concern to their business, regardless of company size, and that
three key challenges stand in the way of achieving shorter
timelines and overall R&D goals:
- Patient recruitment: 70% of
trials are delayed by more than one month, and recruitment is the
leading cause. Such drawn out timelines quickly escalate costs.
Further, today’s current approach to recruitment puts the onus on
investigators, whose training and focus is on treating patients,
not recruiting tactics. Such an issue calls for a solution that
relies on an ecosystem of data, analytics, technology, services and
provider organizations.
- Data quality: Since 2000, the
number of participating trial sites outside of the US has doubled,
and the breadth of clinical information has expanded to include
data from electronic data capture (EDC) systems, medical imaging,
labs, electronic health records (EHR), genomics and biomedical
sensors. The inbound volume and rate of such data sets are
exponentially larger than traditional clinical data; as such, old
methods of capturing, cleaning and analyzing are becoming
antiquated. As the industry shifts from static to adaptive data
management, leveraging machine learning and advanced algorithms (to
identify statistical relationships and outliers) is paramount.
- Patient retention: Patient
drop-out in clinical studies today is estimated to be around 18%,
while the cost of recruiting a patient is 12 times greater than
those associated with proper engagement tactics to retain them. The
introduction of mobile health (mHealth) tools are encouraging more
patient-centric research practices—alleviating patient burden and
improving compliance and retention. Further, integrated technology
platforms, such as mobile apps built on an EDC system, not only
create a single source of truth; they enable sponsors to push data
back to patients for ongoing feedback loops and communications
between researchers and patients.
While respondents’ general data needs differ based on
organizational type, roles and size, the survey indicated that
real-world evidence (RWE) and historical trial data are the two
most sought-after data sets. This is likely attributed to the cost
and time-saving implications of leveraging such data during study
design and execution. Real-world clinical and commercial data can
increase the speed and accuracy of clinical trial site selection,
patient recruitment and cohort generation, while tapping into
patient-level data from historical clinical trials offer the
possibility of early insight during clinical development and
reduced failure rates in Phase II and III studies.
“The volume of data in healthcare is growing at a massive rate,
as the industry enters the exciting realm of RWE, genomics,
historical control arms and high-frequency sensor data. But such
data yields valuable insight only if it is properly integrated,
standardized and analyzed,” said David Lee, Medidata’s chief data
officer. “Fortunately, sponsors and CROs are increasingly
partnering with technology companies that specialize in integrating
new data sources, leveraging machine learning and deploying data
science solutions into clinical development workflows. These
innovations are already streamlining manual, resource-intensive
processes and accelerating timelines to key operational and
scientific milestones. Re-architecting pharmaceutical business
models to optimize use of data-driven insights will increase the
success rate of clinical trials and help improve patients’
lives.”
For more information on leveraging analytics to improve
decision-making, lower R&D costs and shorten clinical research
timelines, join Medidata and SHYFT Analytics for our joint webinar
on June 28, “7 Ways to Compress Your Clinical Trial Timeline.”
To download the full eBook with detailed survey results, visit
here.
Connect with Medidata
Read our blog, Geeks Talk ClinicalTweet this: New survey
conducted by @Medidata & @PharmaVOICE reveals #data wants,
needs & opportunities in #clinicalresearch:
http://ow.ly/bWtK30cLmivFollow us on Twitter: @MedidataFind us on
LinkedIn
About Medidata
Medidata is reinventing global drug and medical device
development by creating the industry's leading cloud-based
solutions for clinical research. Through our advanced applications
and intelligent data analytics, Medidata helps advance the
scientific goals of life sciences customers worldwide, including
over 850 global pharmaceutical companies, biotech, diagnostic and
device firms, leading academic medical centers, and contract
research organizations.
The Medidata Clinical Cloud® brings a new level of quality and
efficiency to clinical trials that empower our customers to make
more informed decisions earlier and faster. Our unparalleled
clinical trial data assets provide deep insights that pave the way
for future growth. The Medidata Clinical Cloud is the primary
technology solution powering clinical trials for 18 of the world's
top 25 global pharmaceutical companies and is used by 18 of the top
25 medical device developers—from study design and planning through
execution, management and reporting.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170621005688/en/
Medidata SolutionsInvestor:Anthony D’Amico, +1
732-767-4331adamico@mdsol.comorMedia:Erik Snider, +1
646-362-2997esnider@mdsol.com
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Apr 2023 to Apr 2024